R&D | October 08, 2025
Hesperos and Bayer Consumer Health develop frst human-on-a-chip model of stress-induced cognitive dysfunction
New study presents a human-relevant stress model for assessing potential therapeutics
New study presents a human-relevant stress model for assessing potential therapeutics
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
RN3161 is engineered to reduce fat while preserving lean mass, setting it apart from current treatment options
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
